The world’s first patient has been treated for knee osteoarthritis (OA) using gum cells from a human donor. 

The patient was treated at Oxford University Hospitals, UK using Allogenic Gingival Fibroblast (aGF) Therapy, a treatment developed by biotechnology startup Scarcell Therapeutics. 

The therapy is designed to prevent immunologic reaction and inhibit inflammation, protect local cells from apoptosis, inhibit cartilage degradation and block nociceptive signal to stop pain. The treatment is currently being studied in a Phase Ib trial at Oxford University Hospital, with 15 patients being evaluated using a single intra-articular injection of aGF Therapy. 

“Gingival cells are an exciting approach to study as donor cells do not trigger rejection by a patient’s immune system, unlike induced pluripotent stem cells (IPS) or embryonic stem cells (ES),” said Professor Antoine Lafont, Founder of Scarcell Therapeutics. 

“As aGF therapy is immune tolerant, it results in cell survival and provides time for the mechanisms of action to affect repair over several months without use of immunosuppressant drugs.” 

“These first-in-human cases mark an exciting milestone in our mission to transform the way osteoarthritis is managed worldwide,” added Sarah Sorrel, CEO of Scarcell.  

“We are proud to lead the way with a comprehensive therapy that has the potential to provide durable relief and structural repair for millions of patients suffering from debilitating knee arthritis.” 

The in-human trial follows a pre-clinical study of more than 800 companion animals with severe osteoarthritis, including dogs and racehorses, receiving aGF Therapy. Pre-clinical data demonstrated the safety and long-term effectiveness (up to two years) of a single injection.  

 

Bruno Quinney, Content Team, DDW